Table 3.
Abnormal outcomes by treatment arm
| Domain | Nifedipine (n = 115) | Atosiban (n = 110) | OR | 95% CI | P | |
|---|---|---|---|---|---|---|
| No. abnormal | No. abnormal | |||||
| Abnormal total score on any questionnaire | ASQ and/or BRIEF‐P and/or CBCL abnormal score | 32/107 (30%) | 38/100 (38%) | 0.71 | 0.39–1.29 | 0.26 |
| Neurodevelopment: ASQ‐3 abnormal a | Communication scale | 9/113 (8.0%) | 9/107 (8.4%) | 0.79 | 0.28–2.17 | 0.64 |
| Gross motor scale | 8/110 (7.3%) | 7/106 (6.6%) | 1.07 | 0.37–3.13 | 0.89 | |
| Fine motor scale | 18/112 (16%) | 14/106 (13%) | 1.46 | 0.65–3.29 | 0.36 | |
| Problem solving scale | 5/113 (4.4%) | 13/107 (12%) | 0.33 | 0.11–0.98 | 0.047 | |
| Personal social scale | 10/113 (8.8%) | 10/107 (9.3%) | 0.98 | 0.37–2.57 | 0.97 | |
| Total neurodevelopmental delay | 28/111 (25%) | 30/107 (28%) | 0.92 | 0.49–1.73 | 0.79 | |
| Executive function: BRIEF‐P abnormal b | Inhibitory self‐control index: inhibit and emotional control scales | 9/108 (8.3%) | 9/103 (8.7%) | 0.94 | 0.36–2.47 | 0.90 |
| Flexibility index: shift and emotional control scales | 10/108 (9.3%) | 12/104 (12%) | 0.73 | 0.30–1.77 | 0.48 | |
| Emergent metacognition index: working memory and plan/organise scale | 6/108 (5.6%) | 10/103 (9.7%) | 0.66 | 0.23–1.94 | 0.45 | |
| Total executive function disorders | 9/108 (8.3%) | 10/102 (9.8%) | 0.79 | 0.31–2.01 | 0.62 | |
| Behaviour: CBCL abnormal c | Internalising scale | 10/111 (9.0%) | 7/104 (6.7%) | 1.32 | 0.48–3.62 | 0.59 |
| Externalising scale | 9/111 (8.1%) | 5/104 (4.8%) | 1.67 | 0.55–5.08 | 0.36 | |
| Total behavioural problems | 10/111 (9.0%) | 7/104 (6.7%) | 1.31 | 0.46–3.74 | 0.62 |
According to the respective manuals, the cut‐off values for defining an abnormal score are:
a
At least one developmental field scoring ≥2 SD below the mean.
b
T‐score of 65 or higher.
c
T‐score of 64 or higher.